The Saint Louis University Division of Nephrology offers comprehensive care for patients with acute and chronic disorders of the kidney and urinary tract.
Our clinical services include inpatient and outpatient hemodialysis, critical care nephrology, continuous renal replacement therapies, peritoneal dialysis, renal transplantation, renal biopsy and imaging, interventional nephrology and advanced hypertension care. Since our inception, our goal has been focused on building a world class comprehensive training program.
Our program has been continuously accredited by the Accreditation Council for Graduate Medical Education (ACGME) for more than 25 years. We have graduated nearly 100 fellows with an American Board of Internal Medicine (ABIM) board pass rate of 95 percent.
Many of our fellows have gone on to successful careers, either in academic medicine or as clinical nephrologists. We offer robust inpatient and outpatient rotations, focused on all forms of renal replacement therapy (hemodialysis, continuous renal replacement therapies, peritoneal dialysis and home therapies), renal transplantation, interventional nephrology, advanced hypertension diagnosis and management, and a wide range of general nephrology problems (glomerular disease, fluid and electrolyte disorders, acute and chronic kidney disease).
- Bahar Bastani, M.D.
- John Edwards, M.D., Ph.D.
Associate Chair of Research
- Danny Issa, M.D.
- Farrukh Koraishy, M.D, Ph.D.
VA Program Director
- Krista Lentine, M.D., Ph.D.
Center for Outcomes
- Kevin J. Martin, MB, BCh, FASN
Clara A Drefs Professor of Internal Medicine
- Geetha Maddukuri, M.D.
- Amy Mosman, PA-C
Hypertension and Dialysis
- Rosemary Ouseph, M.D.
- Marie Philipneri, M.D, Ph.D.
- Paul G. Schmitz, M.D., FASN, FASH
Professor of Internal Medicine
Director, Hypertension Clinic
Training Program Director
- Rupi Sodhi, M.D.
- Thanh-Mai Vo, M.D.
- Hala Yamout, M.D.
Contracts, Grants and Sponsored Research
- The Role of CLIC4 in Angiogenesis.
- Ion Channel Activity of ApoL1 and its Kidney Disease-Associated Variants.
- The Channel Activity of ApoL1 and Progressive Chronic Kidney Disease.
- The Ion Channel Activity of ApoL1 and Podocyte Injury.
- Cost effectiveness of a decision aid to reduce knowledge barriers to pursuit of live kidney donor transplantation.
- Interventions to Increase Pancreas Utilization.
- Effect of Nutrition Education on Dialysis Patient Phosphorus and iPTH Levels.
- Regulation of Nephron Progenitor Cell Self-Renewal and Differentiation.
- Regulation of Renal Progenitor Cell Fate in Normal Kidney Development and Townes-Brocks Syndrome.
- Identifying Genetic Causes of Congenital Renal Disease.
- Evaluation of RGD Integrin Antagonists for Treatment of Kidney Fibrosis.
- Contribution of APOL1 to Gestational Hypertension. Low Birth Weight and Prematurity.
- Long Term Health Outcomes After Live Kidney Donation in African Americans.
- UCLA (Waterman) Research Services Agreement.
- Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity.
- An open-label, prospective randomized, multi-center, Phase II Comparative Trial of Thymoglobulin versus Simulect for the prevention of delayed graft function and acute allograft rejection in renal allograft recipients.
- Liver transplantation: Patient-reported outcomes, healthcare cost and comparative modeling of the simultaneous liver-kidney allocation policy.
- Cost effectiveness of a decision aid to reduce knowledge barriers to pursuit of live kidney donor transplantation
- Modifiable factors affecting live donor disparities (MFALDD).
- Economic Strategies to Reduce Organ Discard Through Risk-Adjusted Payment Mechanisms.
- Central artery pressures and waveform analysis in gestational hypertension and preeclampsia.
- Volume dependency of arterial stiffness.
- A Randomized, Multi-Country, Multicenter, Double -Blind, Parallel, Placebo-controlled Study of the Effects of Atrasentan on Renal outcomes in Subjects with
- Type 2 Diabetes and Nephropathy (SONAR study site).
- Pathophysiological mechanisms of Cardiorenal Syndrome (CRS) with an emphasis on novel treatments targeting bidirectional signaling pathways.